> ## Content Index
> Fetch the complete content index at: https://curo.ghost.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Retatrutide: reading the weight-loss number in a trial paper
- URL: https://curo.ghost.io/retatrutide-reading-trial-weight-numbers/
- Published: 2026-10-15T19:28:08.000Z
- Updated: 2026-10-15T19:28:08.000Z
- Author: Romio
- Tags: Peptide research

Retatrutide trial headlines usually give one weight-loss figure, and the same trial can yield two figures. Five questions help place any figure: which analysis produced it, who was in the trial, how long it ran, whether a journal has published it and which material it describes.

The [retatrutide trials guide](https://sites.google.com/view/retatrutide-research/retatrutide-trials?ref=curo.ghost.io) lists each published result. The [retatrutide vs tirzepatide comparison](https://sites.google.com/view/retatrutide-research/retatrutide-vs-tirzepatide?ref=curo.ghost.io) shows why two trials with similar designs still do not make a head-to-head result.

### Which analysis produced the figure?

TRIUMPH-2 shows the effect of this choice. The Lancet paper reported a mean change of -18.8% for the retatrutide group with the largest change, using the treatment-regimen estimand. Lilly's news release reported -20.8% for the same group using the efficacy estimand, which represents efficacy had all randomized participants stayed on study intervention without starting prohibited weight management treatments. Sources: [2026 Lancet, PMID 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/?ref=curo.ghost.io) and [Lilly news release, July 23, 2026](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html?ref=curo.ghost.io).

### Who was in the trial?

Placebo results move with the population. In TRIUMPH-1, adults with obesity and no diabetes lost 3.9% on placebo over 80 weeks. In TRIUMPH-2, adults with obesity and type 2 diabetes lost 5.1% on placebo over the same 80 weeks. Sources: [PMID 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/?ref=curo.ghost.io) and [PMID 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/?ref=curo.ghost.io).

### How long did the trial run?

Trial length changes what a figure means. The phase 2 obesity trial reported weight change at 24 and 48 weeks, and the figures grew with time in every retatrutide group. Source: [2023 New England Journal of Medicine, PMID 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/?ref=curo.ghost.io).

### Is the figure a paper or a topline release?

TRIUMPH-3 and TRIUMPH-4 have sponsor topline figures and no results paper in PubMed on October 15, 2026, so their numbers come from the sponsor's release alone. Sources: [Lilly news release, July 23, 2026](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html?ref=curo.ghost.io) and [Lilly news release, December 11, 2025](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html?ref=curo.ghost.io).

### Match the material to the paper

A trial result belongs to the molecule that Lilly tested. A vial in a laboratory is documented by its own lot report. The [Reta 10mg Kit listing at Curo](https://curo.you/u/google-sites?to=%2Freta-gl3-kit&utm%5Fsource=ghost&utm%5Fmedium=referral&utm%5Fcampaign=retatrutide&utm%5Fcontent=ghost%5Fretatrutide%5Fproduct) identifies a supplier's material, and [Curo's lot-certificate library](https://curo.you/u/google-sites?to=%2Fcoa&utm%5Fsource=ghost&utm%5Fmedium=referral&utm%5Fcampaign=retatrutide&utm%5Fcontent=ghost%5Fcoa) and [Curo's testing-method page](https://curo.you/u/google-sites?to=%2Ftesting&utm%5Fsource=ghost&utm%5Fmedium=referral&utm%5Fcampaign=retatrutide&utm%5Fcontent=ghost%5Ftesting) describe how lot reports are organized.

Sources checked October 15, 2026\. Reference information for laboratory research.